Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae
- 1 June 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (6) , 1654-1659
- https://doi.org/10.1128/aac.45.6.1654-1659.2001
Abstract
The incidence of ciprofloxacin resistance in Streptococcus pneumoniae is low but steadily increasing, which raises concerns regarding the clinical impact of potential cross-resistance with newer fluoroquinolones. To investigate this problem, we utilized an in vitro pharmacodynamic model and compared the activities of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin to that of ciprofloxacin against two laboratory-derived, ciprofloxacin-resistant derivatives of S. pneumoniae (strains R919 and R921). Ciprofloxacin resistance in these strains involved the activity of a multidrug efflux pump and possibly, for R919, a mutation resulting in an amino acid substitution in GyrA. Gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin achieved 99.9% killing of both R919 and R921 in ≤28 h. With respect to levofloxacin, significant regrowth of both mutants was observed at 48 h ( P < 0.05). For gatifloxacin, grepafloxacin, moxifloxacin, and trovafloxacin, regrowth was minimal at 48 h, with each maintaining 99.9% killing against both mutants. No killing of either R919 or R921 was observed with exposure to ciprofloxacin. During model experiments, resistance to gatifloxacin, grepafloxacin, moxifloxacin, and trovafloxacin did not develop but the MICs of ciprofloxacin and levofloxacin increased 1 to 2 dilutions for both R919 and R921. Although specific area under the concentration-time curve from 0 to 24 h (AUC 0–24 )/MIC and maximum concentration of drug in serum ( C max )/MIC ratios have not been defined for the fluoroquinolones with respect to gram-positive organisms, our study revealed that significant regrowth and/or resistance was associated with AUC 0–24 /MIC ratios of ≤31.7 and C max /MIC ratios of ≤3.1. It is evident that the newer fluoroquinolones tested possess improved activity against S. pneumoniae , including strains for which ciprofloxacin MICs were elevated.Keywords
This publication has 47 references indexed in Scilit:
- Will pneumococci put quinolones in their place?Journal of Antimicrobial Chemotherapy, 1999
- Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in CanadaNew England Journal of Medicine, 1999
- GatifloxacinDrugs, 1999
- Community‐Acquired Pneumonia in Adults: Guidelines for ManagementClinical Infectious Diseases, 1998
- Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?Journal of Antimicrobial Chemotherapy, 1997
- Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteriaJournal of Antimicrobial Chemotherapy, 1995
- Activity of CP 99, 219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepaloxacin against penicillin-susceptible and -resistant pneumococciJournal of Antimicrobial Chemotherapy, 1995
- Management of Infections Caused by Antibiotic-Resistant Streptococcus PneumoniaeNew England Journal of Medicine, 1994
- Induction of Resistance of Streptococcus pneumoniae to Quinolones in vitroChemotherapy, 1993
- Antimicrobial Resistance in Streptococcus pneumoniae: An OverviewClinical Infectious Diseases, 1992